12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Company News  |  Other News

Theravance infectious, gastrointestinal, pulmonary news

Theravance plans to split into two publicly traded companies to separate its partnered late-stage respiratory assets from its R&D. One company - Royalty Management Co. - will manage all development and commercial responsibilities, plus potential royalty revenues, for long-acting adrenergic receptor beta 2 agonist (LABA) products partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.). The products, which are in development for asthma and...

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >